Hideho Okada MD
Associate Professor, Neurological Surgery, University of Pittsburgh School of Medicine
Join to View Full Profile
1450 3rd StreetSan Francisco, CA 94158
Phone+1 415-476-1637
Dr. Okada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Nagoya University - School of MedicineClass of 1991
Certifications & Licensure
PA State Medical License 2004 - 2014
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2010
Clinical Trials
- H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas Start of enrollment: 2016 Nov 18
Publications & Presentations
PubMed
- FcRn-silencing of IL-12Fc prevents toxicity of local IL-12 therapy and prolongs survival in experimental glioblastoma.Michal Beffinger, Linda Schellhammer, Betül Taskoparan, Sereina Deplazes, Ulisse Salazar
Nature Communications. 2025-05-22 - 1 citationsGlioma-neuronal circuit remodeling induces regional immunosuppression.Takahide Nejo, Saritha Krishna, Akane Yamamichi, Senthilnath Lakshmanachetty, Christian Jimenez
Nature Communications. 2025-05-22 - 2 citationsResponse Assessment in Neuro-Oncology (RANO) 2009-2025: Broad Scope and Implementation - A Progress Report.Martin J van den Bent, Michael A Vogelbaum, Tim Cloughesy, Norbert Galldiks, Nathalie L Albert
Neuro-Oncology. 2025-05-03
Journal Articles
- Immunotherapy of Primary Brain Tumors: Facts and HopesHideho Okada, MD, Clinical Cancer Research
- Single-Cell Profiling of Human Gliomas Reveals Macrophage Ontogeny as a Basis for Regional Differences in Macrophage Activation in the Tumor MicroenvironmentDaniel A Lim, S John Liu, Manish Aghi, Hideho Okada, Nduka M Amankulor, Arnold R Kriegstein, BioMed Central
Press Mentions
Jumbled Proteins Paint a Bold Target on the Backs of Brain TumorsFebruary 19th, 2025- Killer T Cells Programmed for Tissue- and Tumor-Specific TargetingDecember 6th, 2024
- Molecular Zip Code Draws Killer T Cells to Brain TumorsDecember 5th, 2024
- Join now to see all
Grant Support
- Preclinical development of breakthrough immunotherapy for brain tumorsUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
